233 related articles for article (PubMed ID: 30425976)
1. Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma.
Korhan P; Yılmaz Y; Bağırsakçı E; Güneş A; Topel H; Carr BI; Atabey N
Can J Gastroenterol Hepatol; 2018; 2018():7568742. PubMed ID: 30425976
[TBL] [Abstract][Full Text] [Related]
2. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma.
Negm O; Abou Saif S; El Gharib M; Yousef M; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):317-321. PubMed ID: 27893491
[TBL] [Abstract][Full Text] [Related]
3. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
Walenga JM; Lyman GH
Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
[TBL] [Abstract][Full Text] [Related]
4. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications.
Zanetto A; Campello E; Pelizzaro F; Farinati F; Burra P; Simioni P; Senzolo M
Liver Int; 2022 Jun; 42(6):1229-1240. PubMed ID: 35129286
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma.
Wang Y; Attar BM; Hinami K; Fuentes HE; Jaiswal P; Zhang H; Simons-Linares CS; Tafur AJ
J Gastrointest Cancer; 2018 Sep; 49(3):275-282. PubMed ID: 28374272
[TBL] [Abstract][Full Text] [Related]
6. Heparin and anticoagulation.
Onishi A; St Ange K; Dordick JS; Linhardt RJ
Front Biosci (Landmark Ed); 2016 Jun; 21(7):1372-92. PubMed ID: 27100512
[TBL] [Abstract][Full Text] [Related]
7. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].
Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP
Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients.
Faccia M; Santopaolo F; Gasbarrini A; Pompili M; Zocco MA; Ponziani FR
Intern Emerg Med; 2022 Aug; 17(5):1327-1334. PubMed ID: 35076898
[TBL] [Abstract][Full Text] [Related]
10. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
11. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
13. The heparins and cancer: review of clinical trials and biological properties.
Castelli R; Porro F; Tarsia P
Vasc Med; 2004 May; 9(3):205-13. PubMed ID: 15675186
[TBL] [Abstract][Full Text] [Related]
14. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
17. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer.
Tran QN
Am J Hosp Palliat Care; 2010 Sep; 27(6):416-9. PubMed ID: 20197558
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?
García-Escobar I; Beato-Zambrano C; Muñoz Langa J; Brozos Vázquez E; Obispo Portero B; Gutiérrez-Abad D; Muñoz Martín AJ;
Clin Transl Oncol; 2018 Sep; 20(9):1097-1108. PubMed ID: 29470777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
